Joseph L Regan
Overview
Explore the profile of Joseph L Regan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Erdem M, Lee K, Hardt M, Regan J, Kobelt D, Walther W, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339354
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. The high mortality is directly associated with metastatic disease, which is thought to be initiated by colon...
2.
Regan J
Methods Cell Biol
. 2022 Aug;
171:163-171.
PMID: 35953199
Organoids recapitulate the cellular heterogeneity, functionality, architecture and molecular signature of the organ or diseased tissue from which they are derived. They thus provide a bridge between traditional 2D culture...
3.
Regan J, Schumacher D, Staudte S, Steffen A, Lesche R, Toedling J, et al.
iScience
. 2022 Jun;
25(7):104498.
PMID: 35720265
Recent evidence demonstrates that colon cancer stem cells (CSCs) can generate neurons that synapse with tumor innervating fibers required for tumorigenesis and disease progression. Greater understanding of the mechanisms that...
4.
Regan J
STAR Protoc
. 2022 Mar;
3(1):101225.
PMID: 35300001
Quiescent cancer stem cells (qCSCs) are a major source of posttreatment relapse, but methods to identify molecular targets for qCSC elimination are limited. Here, we present a protocol using the...
5.
Regan J, Schumacher D, Staudte S, Steffen A, Lesche R, Toedling J, et al.
iScience
. 2021 Jun;
24(6):102618.
PMID: 34142064
Recent data suggest that therapy-resistant quiescent cancer stem cells (qCSCs) are the source of relapse in colon cancer. Here, using colon cancer patient-derived organoids and xenografts, we identify rare long-term...
6.
Schumacher D, Regan J, Przybilla D, Schafer R
Methods Mol Biol
. 2021 May;
2262:349-360.
PMID: 33977489
Human cell line models have been widely used for testing of novel anticancer compounds and for predicting clinical response to monotherapies and combinatorial therapies. For many years, standard monolayer culture...
7.
Regan J, Smalley M
NPJ Breast Cancer
. 2020 Aug;
6:32.
PMID: 32793804
The identification and molecular characterization of cellular hierarchies in complex tissues is key to understanding both normal cellular homeostasis and tumorigenesis. The mammary epithelium is a heterogeneous tissue consisting of...
8.
Regan J
Mol Cell Oncol
. 2018 Sep;
5(3):e1445940.
PMID: 30250897
Colon cancer is a heterogeneous tumor driven by subpopulations of cancer stem cells (CSCs). We recently used patient-derived organoids (PDOs) to demonstrate that CSC survival is regulated by autocrine non-canonical...
9.
Klutzny S, Anurin A, Nicke B, Regan J, Lange M, Schulze L, et al.
Cell Death Dis
. 2018 Feb;
9(2):192.
PMID: 29416006
Cancer stem cells (CSCs) are involved in metastasis and resistance development, thus affecting anticancer therapy efficacy. The underlying pathways required for CSC maintenance and survival are not fully understood and...
10.
Regan J, Schumacher D, Staudte S, Steffen A, Haybaeck J, Keilholz U, et al.
Cell Rep
. 2017 Dec;
21(10):2813-2828.
PMID: 29212028
Colon cancer is a heterogeneous tumor driven by a subpopulation of cancer stem cells (CSCs). To study CSCs in colon cancer, we used limiting dilution spheroid and serial xenotransplantation assays...